OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-24.99%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$160M
AUM Growth
+$160M
(-33%)
Cap. Flow
-$22.8M
Cap. Flow
% of AUM
-14.22%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
67
New
14
Increased
18
Reduced
12
Closed
15
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$4.26M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$3.45M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$2.66M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$2.59M |
| 5 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$2.46M |
Top Sells
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
$6.24M |
| 2 |
CEMP
Cempra, Inc.
CEMP
|
$6.23M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$4.5M |
| 4 |
Tonix Pharmaceuticals
TNXP
|
$4.33M |
| 5 |
AVGR
Avinger, Inc. Common Stock
AVGR
|
$4.32M |
Sector Composition
| 1 | Healthcare | 77.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axogen
AXGN
$723M
| $11.4M | 7.09% |
2,120,000
| – | – |
|
|
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $7.99M | 4.98% |
1,250,000
-60,000
| -5% | -$383K |
|
3
Ultragenyx Pharmaceutical
RARE
$3.09B
| $6.96M | 4.34% |
110,000
| – | – |
|
4
FibroGen
FGEN
$49.3M
| $6.92M | 4.31% |
325,000
| – | – |
|
|
GNMX
5
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $6.85M | 4.27% |
1,557,700
+167,700
| +12% | +$738K |
|
|
ADMS
6
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $6.06M | 3.78% |
320,000
+130,000
| +68% | +$2.46M |
|
|
TVRD
7
Tvardi Therapeutics, Inc. Common Stock
TVRD
$277M
| $5.32M | 3.32% |
855,000
+428,000
| +100% | +$2.66M |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $5.29M | 3.3% |
165,000
+65,000
| +65% | +$2.08M |
|
|
AMAG
9
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $5.15M | 3.21% |
220,000
+70,000
| +47% | +$1.64M |
|
10
Harrow
HROW
$1.4B
| $4.96M | 3.09% |
1,250,000
+45,000
| +4% | +$179K |
|
11
Assertio
ASRT
$76.4M
| $4.53M | 2.82% |
325,000
+25,000
| +8% | +$348K |
|
|
12
Agios Pharmaceuticals
AGIO
$2.28B
| $4.26M | 2.66% |
+105,000
| New | +$4.26M |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $3.97M | 2.48% |
220,000
-55,000
| -20% | -$993K |
|
14
Geron
GERN
$938M
| $3.87M | 2.41% |
1,325,000
-500,000
| -27% | -$1.46M |
|
|
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $3.85M | 2.4% |
590,000
+90,000
| +18% | +$587K |
|
16
Codexis
CDXS
$227M
| $3.67M | 2.29% |
1,178,500
-421,500
| -26% | -$1.31M |
|
17
TG Therapeutics
TGTX
$4.72B
| $3.54M | 2.21% |
415,000
+115,000
| +38% | +$980K |
|
|
CMRX
18
DELISTED
Chimerix, Inc.
CMRX
| $3.45M | 2.15% |
+675,000
| New | +$3.45M |
|
|
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.38M | 2.11% |
80,000
-25,000
| -24% | -$1.06M |
|
|
IMMU
20
DELISTED
Immunomedics Inc
IMMU
| $3.31M | 2.07% |
1,325,000
+1,035,000
| +357% | +$2.59M |
|
21
Xenon Pharmaceuticals
XENE
$3.03B
| $2.8M | 1.74% |
400,000
+100,000
| +33% | +$699K |
|
|
AMRN
22
Amarin Corp
AMRN
$314M
| $2.69M | 1.68% |
1,760,000
| – | – |
|
23
Indaptus Therapeutics
INDP
$6.81M
| $2.63M | 1.64% |
638,000
+8,000
| +1% | +$33K |
|
|
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $2.45M | 1.53% |
273,800
+53,800
| +24% | +$482K |
|
|
EGRX
25
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $2.43M | 1.52% |
60,000
-25,000
| -29% | -$1.01M |
|